KemPharm, Inc. Stock News

$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a con...

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company's common stock (the “Inducement Awards”) to four new employe...

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026 , at 4:30 p.m. ET BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a...

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population

LOS ANGELES--(BUSINESS WIRE)---- $ZVRA--ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law.